Molecular Technologies in the Clinical Diagnostic Laboratory

Saiki R.K. , Gelfand D.H. , Stoffel S. . Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988; 239(4839): 487–491.

Green M.R. , Sambrook J. . Molecular Cloning: A Laboratory Manual. 4th ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2012.

Vogelstein B. , Kinzler K.W. . Digital PCR. Proc Natl Acad Sci U S A. 1999; 96(16): 9236–9241.

Sanders R. , Huggett J.F. , Bushell C.A. . Evaluation of digital PCR for absolute DNA quantification. Anal Chem. 2011; 83(17): 6474–6484.

Day E. , Dear P.H. , McCaughan F. . Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine. Methods. 2013; 59(1): 101–107.

McCaughan F. , Dear P.H. . Single-molecule genomics. J Pathol. 2010; 220(2): 297–306.

Hindson B.J. , Ness K.D. , Masquelier D.A. . High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011; 83(22): 8604–8610.

Zhong Q. , Bhattacharya S. , Kotsopoulos S. . Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. Lab Chip. 2011; 11(13): 2167–2174.

Vogelstein B. , Papadopoulos N. , Velculescu V.E. . Cancer genome landscapes. Science. 2013; 339(6127): 1546–1558.

Marin J.J. , Sanchez de Medina F. , Castaño B. . Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab Rev. 2012; 44(2): 148–172.

Navin N. , Krasnitz A. , Rodgers L. . Inferring tumor progression from genomic heterogeneity. Genome Res. 2010; 20(1): 68–80.

Eberhard D.A. , Giaccone G. , Johnson B.E. . Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008; 26(6): 983–994.

Normanno N. , Tejpar S. , Morgillo F. . Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009; 6(9): 519–527.

Wang J. , Ramakrishnan R. , Tang Z. . Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. Clin Chem. 2010; 56(4): 623–632.

Wang Z. , Chen R. , Wang S. . Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PloS One. 2014; 9(11): e110780.

Laurent-Puig P. , Pekin D. , Normand C. . Clinical relevance of KRAS-mutated subclones detected with picodroplet digital pcr in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res. 2015; 21(5): 1087–1097.

Singer G. , Oldt R 3rd , Cohen Y. . Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003; 95(6): 484–486.

Diehl F. , Schmidt K. , Durkee K.H. . Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008; 135(2): 489–498.

Stranger B.E. , Forrest M.S. , Dunning M. . Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007; 315(5813): 848–853.

Oehler V.G. , Qin J. , Ramakrishnan R. . Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia. 2009; 23(2): 396–399.

Yung T.K. , Chan K.C. , Mok T.S. . Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009; 15(6): 2076–2084.

Li N. , Ma J. , Guarnera M.A. . Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014; 140(1): 145–150.

Heyries K.A. , Tropini C. , Vaninsberghe M. . Megapixel digital PCR. Nat Methods. 2011; 8(8): 649–651.

Sanger F. , Nicklen S. , Coulson A.R. . DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74(12): 5463–5467.

Applied Biosystems. DNA Sequencing by Capillary Electrophoresis. 2nd ed. Foster City, CA: Applied Biosystems; 2009. http://www.griffith.edu.au/__data/assets/pdf_file/0007/160369/DNA-Sequencing-Chemistry-Guide.pdf. Accessed April 20, 2015.

Jurinke C. , van den Boom D. , Cantor C.R. . Automated genotyping using the DNA MassArray technology. Methods Mol Biol. 2001; 170: 103–116.

Jurinke C. , van den Boom D. , Cantor C.R. . Automated genotyping using the DNA MassArray technology. Methods Mol Biol. 2002; 187: 179–192.

Karas M. , Hillenkamp F. . Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem. 1988; 60: 2299–2301.

Tanaka K. , Waki H. , Ido Y. . Protein and polymer analyses up to m/z 100,000 by laser ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 1988; 2(8): 151–153.

Takeda N. , Pomerantz S.C. , McCloskey J.A. . Detection of ribose-methylated nucleotides in enzymatic hydrolysates of RNA by thermospray liquid chromatography-mass spectrometry. J Chromatogr. 1991; 562 (1-2): 225–235.

Karas M. , Bachmann D. , Hillenkamp F. . Influence of the wavelength in high-irradiance ultraviolet laser desorption mass spectrometry of organic molecules. Analytical Chemistry. 1985; 57(14): 2935–2939

Scheper T. , Hoheisel J.D. , eds. Chip Technology. Volume 77. Berlin: Springer-Verlag; 2002.

Ahmad F. , Babalola O.O. . Application of mass spectrometry as rapid detection tool in plant nematology. Appl Spectr Rev. 2014; 19(1): 1–10.

Nordhoff E. , Ingendoh A. , Cramer R. . Matrix-assisted laser desorption/ionization mass spectrometry of nucleic acids with wavelengths in the ultraviolet and infrared. Rapid Commun Mass Spectrom. 1992; 6(12): 771–776.

Braun A. , Little D.P. , Köster H. . Detecting CFTR gene mutations by using primer oligo base extension and mass spectrometry. Clin Chem. 1997; 43(7): 1151–1158.

Edenberg H.J. , Liu Y. . Laboratory methods for high-throughput genotyping. Cold Spring Harb Protoc. 2009; 4(11): 1–9.

Farkas D.H. , Miltgen N.E. , Stoerker J. . The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model. J Mol Diagn. 2010; 12(5): 611–619.

Su K.Y. , Chen H.Y. , Li K.C. . Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012; 30(4): 433–440.

Mullen M.P. , Creevey C.J. , Berry D.P. . Polymorphism discovery and allele frequency estimation using high-throughput DNA sequencing of target-enriched pooled DNA samples. BMC Genomics. 2012; 13: 16.

Agena Bioscience. Lungcarta panel. http://agenabio.com/lungcar-ta-panel. Accessed May 4, 2015.

Quinn A.M. , Hickson N. , Adaway M. . Diagnostic mutation profiling and validation of non-small-cell lung cancer small biopsy samples using a high throughput platform. J Thorac Oncol. 2015; 10(5): 784–792.

Agena Bioscience. High-throughput somatic mutation profiling for lung cancer research. http://agenabio.com/sites/default/files/51-20013R1.0-Lung-Carta-Flyer_WEB.pdf. Accessed May 4, 2015.

Geiss G.K. , Bumgarner R.E. , Birditt B. . Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26(3): 317–325.

Textoris J. , Loriod B. , Benayoun L. . An evaluation of the role of gene expression in the prediction and diagnosis of ventilator-associated pneumonia. Anesthesiology. 2011; 115(2): 344–352.

Brahmachary M. , Guilmatre A. , Quilez J. . Digital genotyping of macrosatellites and multicopy genes reveals novel biological functions associated with copy number variation of large tandem repeats. PLoS Genet. 2014; 10(6): e1004418.

Geiss G.K. , Bumgarner R.E. , Birditt B. . Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26(3): 317–325.

Nielsen T.O. , Parker J.S. , Leung S. . A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010; 16(21): 5222–5232.

Chen J. , Ye Y. , Sun H. . Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol. 2013; 71(1): 265–272.

Nielsen T. , Wallden B. , Schaper C. . Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014; 14: 177.

NanoString Technologies. Prosigna Website overview. http://prosigna.com/overview. Published 2015. Accessed April 20, 2015.

Dowsett M. , Sestak I. , Lopez-Knowles E. . Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013; 31(22): 2783–2790.

NanoString Technologies. nCounter: leukemia fusion gene expression assay. Published July 18, 2011. http://www.nanostring.com/media/pdf/PDS_nCounter_Leukemia_Fusion.pdf. Accessed April 20, 2015.

Ullal A.V. , Peterson V. , Agasti S.S. . Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Science Transl Med. 2014; 6(219): 219ra9.

Botella L.M. , Albiñana V. , Ojeda-Fernandez L. . Research on potential biomarkers in hereditary hemorrhagic telangiectasia. Front Genet. 2015; 6: 115.

Rehm H.L. , Bale S.J. , Bayrak-Toydemir P. ; Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Commitee. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013; 15(9): 733–747.

Grada A. , Weinbrecht K. . Next-generation sequencing: methodology and application. J Invest Dermatol. 2013; 113(8): e11.

Spisák S. , Guttman A. . From chemical genomics to chemical proteomics: the power of microarray technology. In: Darvas F. , Guttman A. , Dormán G. . Chemical Genomics and Proteomics. 2nd ed. Boca Raton, FL: CRC Press; 2013: 81–122.

Flusberg B.A. , Webster D.R. , Lee J.H. . Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat Methods. 2010; 7(6): 461–465.

Abrams J. , Conley B. , Mooney M. . National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014: 71–76.

Craig D.W. , O'Shaughnessy J.A. , Kiefer J.A. . Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013; 12(1): 104–116.

Liang W.S. , Craig D.W. , Carpten J. . Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One. 2012; 7(10): e43192.

Frampton G.M. , Fichtenholtz A. , Otto G.A. . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11): 1023–1031.

Leary R.J. , Sausen M. , Kinde I. . Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012; 4(162): 162ra154.

Deverka P.A. , Dreyfus J.C. . Clinical integration of next generation sequencing: coverage and reimbursement challenges. J Law Med Ethics. 2014; 42(Suppl 1): 22–41.

Javitt G.H. , Carner K.S. . Regulation of next generation sequencing. J Law Med Ethics. 2014; 42(Suppl 1): 9–21.

Yu B. . Setting up next-generation sequencing in the medical laboratory. Methods Mol Biol. 2014; 1168: 195–206.

Gargis A.S. , Kalman L. , Berry M.W. . Assuring the quality of next-generation sequencing in clinical laboratory practice. Nature Biotechnol. 2012; 30(11): 1033–1036.

Chin L. , Andersen J.N. , Futreal P.A. . Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011; 17(3): 297–303.

Fenstermacher D.A. , Wenham R.M. , Rollison D.E. . Implementing personalized medicine in a cancer center. Cancer J. 2011; 17(6): 528–536.

Weinstein J.N. , Collisson E.A. , Mills G.B. ; Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genet. 2013; 45(10): 1113–1120.

Johnson D.B. , Dahlman K.H. , Knol J. . Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist. 2014; 19(6): 616–622.

FoundationOne. Technical information and test overview. http://foundationone.com/docs/FM_TechnicalOverview_HEM-I-001-20150105.pdf. Accessed May 7, 2015.

Lopez-Chavez A. , Thomas A. , Rajan A. . Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015; 33(9): 1000–1007.

Marusyk A. , Almendro V. , Polyak K. . Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev. 2012; 12(5): 323–334.

Gerlinger M. , Rowan A.J. , Horswell S. . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10): 883–892.

Anderson K. , Lutz C. , van Delft F.W. . Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011; 469(7330): 356–361.

Ruiz C. , Lenkiewicz E. , Evers L. . Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A. 2011; 108(29): 12054–12059.

Stolze B. , Reinhart S. , Bulllinger L. . Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015; 5: 8535.

Kodaz H. , Hacibekiroglu I. , Erdogan B. . Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. Mol Clin Oncol. 2015; 3(1): 179–184.

Deininger M. . Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw. 2005; 3(6): 757–768.

Corless C.L. , Heinrich M.C. . Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008; 3: 557–586.

Spagnolo F. , Ghiorzo P2 , Orgiano L3 . BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015; 8: 157–168.

Nazarian R. , Shi H. , Wang Q. . Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326): 973–977.

Engelman J.A. , Zejnullahu K. , Mitsudomi T. . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827): 1039–1043.

Diaz L.A. Jr , Williams R.T. , Wu J. . The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486(7404): 537–540.

Wagle N. , Emery C. , Berger M.F. . Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011; 29(22): 3085–3096.

Willyard C. . ‘Basket studies’ will hold intricate data for cancer drug approvals. Nat Med. 2013; 19(6): 655.

Prahallad A. , Sun C. , Huang S. . Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387): 100–103.

Stites E.C. . The response of cancers to BRAF inhibition underscores the importance of cancer systems biology. Sci Signal. 2012; 5(246): pe46.

Jones S. , Anagnostou V. , Lytle K. . Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015; 7(283): 283ra53.

US Department of Health and Human Services; US Food and Drug Administration. Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development. Silver Spring, MD: US Department of Health and Human Services. Published October 2013. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf. Accessed April 20, 2015.

Patel J.N. , Mandock K. , McLeod H.L. . Clinically relevant cancer biomarkers and pharmacogenetic assays. J Oncol Pharm Pract. 2014; 20(1): 65–72.

MacConaill L.E. , Van Hummelen P. , Meyerson M. . Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov. 2011; 1(4): 297–311.

Mao M. , Tian F. , Mariadason J.M. . Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013; 19(3): 657–667.

Mattocks C.J. , Morris M.A. , Matthijs G. . A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet. 2010; 18(12): 1276–1288.

Botkin J.R. , Teutsch S.M. , Kaye C.I. . Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med. 2010; 12(4): 228–235.

US Food and Drug Administration. Framework for regulatory oversight of laboratory developed tests; draft guidance for industry, Food and Drug Administration staff, and clinical laboratories; availability. Fed Regist. 2014; 79(192): 59776–59779.

Caffrey M.K. . When science outpaces payers: molecular diagnostics pose reimbursement dilemmas. OncLive. Published September 17, 2104. http://www.onclive.com/publications/oncology-live/2014/august-2014/when-sci-ence-outpaces-payers-molecular-diagnostics-pose-reimbursement-dilemmas. Accessed May 7, 2015.

California Healthcare Institute (CHI). A New Era for Diagnostics: Personalized Healthcare and the Future of Medicine. La Jolla, CA: CHI. http://www.chi.org/uploadedFiles/CHI_Diagnostics_White_Paper_12-10.pdf. Accessed May 7, 2015.

Fugel H.J. , Nuijten M. , Faulkner E. . The application of economics concepts to stratified medicine–use of health economics data to support market access for stratified medicine interventions. J Med Econ. 2014; 17(5): 305–311.

Fugel H.J. , Nuijten M. , Postma M. . Stratified medicine and reimbursement issues. Front Pharmacol. 2012; 3: 181.

Burns J. . Low 2013 molecular rates may bankrupt some labs. Dark Rep. 2013; 1–6. http://www.darkreport.com/PDF/Low-2013-Molecular-Test-Rates-May-Bankrupt-Some-Pathology-Labs.pdf. Accessed May 4, 2015.